Apeloa Pharmaceutical (000739.SZ) subsidiary obtains the registration certificate for simvastatin sodium sustained-release tablets.

Apeloa Pharmaceutical (000739.SZ) announced that its controlling subsidiary Zhejiang Puolokangyu Pharmaceutical Co., Ltd. ("Kangyu Pharmaceutical") has received the Drug Registration Certificate for the Controlled Release Tablets of Fluvastatin Sodium issued by the National Medical Products Administration. Fluvastatin is a fully synthetic cholesterol-lowering drug, which is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. It inhibits the conversion of HMG-CoA to mevalonic acid, which is a precursor of sterols including cholesterol. The main site of action of this product is in the liver, where it inhibits the synthesis of endogenous cholesterol, reduces the cholesterol content in liver cells, stimulates the synthesis of low-density lipoprotein (LDL) receptors, increases the uptake of LDL particles, and lowers plasma total cholesterol concentrations.